Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

New Trial for Smokers: Novel Chemo Agent Pralatrexate Targeting Potential Weakness for Tarceva

Please Note: New Treatments Have Emerged Since this Original Post
Author
Howard (Jack) West, MD

I've described in a prior post and many of my comments here how tarceva and iressa, oral targeted therapies against EGFR, have been pretty consistently impressive in never-smokers. Not infallibly great, but these agents have shown high response rates in the 25-50% range for never-smokers, and have also been pretty favorable for remote and minimal smokers. These groups have a high incidence of their tumor having an EGFR activating mutation. In the randomized trial that compared tarceva to placebo and showed a significant survival benefit, known as the NCI-Canada BR.21 study, tarceva more than doubled the survival of never-smokers compared with placebo. Among current or former smokers, the trend for tarceva was in the right direction, but it was much less dramatic, with an approximately 13% improvement in survival over the time course of the study. So far I've talked a lot about the favorable results for EGFR inhibitors in lifelong nonsmokers or minimal prior smokers, but the flipside of this is to focus on the less impressive results among smokers, who comprise more than 80% of the lung cancer population. One new trial is attempting to take advantage of that potential weakness and test a new standard chemotherapy against tarceva in smokers in hopes of proving that the standard chemo is superior (link here).

I'll cover the details and available history on the new drug, pralatrexate, in my next post. What's really interesting, adding a personal dimension to the story, is that this drug is being developed by Allos Therapeutics, where the Chief Medical Officer is Dr. Pablo Cagnoni. That doesn't mean anything to you yet, but the interesting part is that Dr. Cagnoni's prior job was as Vice President of Medical Affairs and Translational Research at OSI Pharmaceuticals, which developed tarceva and the BR.21 trial. So clearly he has an intimate knowledge of tarceva and some ideas about its strengths and weaknesses. And after leaving the old job, he and the folks at Allos are taking aim at a potential Achilles' heel for tarceva, figuring that beating it in the large population of current or ex-smokers may be easy pickings.

The trial will be a randomized phase IIb, which to me means that it will be basically like a phase III trial but with too few people to really be done exactly the way you'd do it with enough money. Enrolling second line advanced NSCLC patients who have previously received platinum-based chemo, the trial will accrue 160 patients from 50 sites internationally. This is too small to expect the FDA would approve it, but it could certainly boost interest in the new drug pralatrexate if the preliminary trial is positive. The trial is being run by Dr. Karen Kelly, who heads the oncology program at the University of Kansas and is a world leader in lung cancer, and also a very nice friend who gave us a sweet baby gift of a cool shirt that says "The Future of Rock & Roll":

Future of Rock & Roll (But I digress).

I must say that I think this is a smart and promising strategy for trying to get a new chemo drug approved for lung cancer. Most oncologists perceive that chemo is a little bit more active than EGFR inhibitors like Tarceva or Iressa, or they're at least more comfortable giving it, with the decades of experience with conventional chemotherapy. But some recent trials suggest that iressa performed comparably to single agent taxotere (prior post here) or navelbine (prior post here) in head to head comparisons. Interestingly, those trials didn't indicate that there are subsets that do much better with chemo or EGFR inhibitor, which countered our expectations (mine, at least). So it remains to be seen whether tarceva will be more or less comparable to pralatrexate, or a currently available standard chemo, in a smoking population. For now, I think this is a very interesting and new approach to drug development, with the added intrigue of a the backstory that Dr. Cagnoni left OSI and is now thinking about the potential weaknesses of a drug that he helped develop several years ago.

Of course, what is most important is that this line of research could very possibly lead to a new drug for lung cancer. I'll describe what we know about pralatrexate next.

Next Previous link

Previous PostNext Post

Related Content

Image
Clinical Trials Storytelling 2025
Article
GRACE is pleased to introduce three amazing individuals participating in the 2024-25 GRACE Clinical Trials Experiences Storytelling Program
Article
Imagine your body's defense system, the lymphatic system, suddenly turning against you. This is the reality for those facing lymphoma, a cancer of the immune system's crucial network. This article delves into the complexities of lymphoma, exploring its various forms, from the aggressive to the indolent, and examining the latest breakthroughs in treatment, including the groundbreaking POLARIX trial and cutting-edge therapies for relapsed cases. Whether you're a patient, a loved one, or simply curious about this complex disease, this comprehensive overview will provide valuable insights into the current state of lymphoma care and the promising future of research.
Image
Melanoma Video Library
Video
In these videos, Dr. Autumn Starnes gives an overview of melanoma's prevalence and risk factors. She also discusses the ABCDE method of self-screening for skin cancer, common misconceptions regarding people of color, and melanoma, and how a person can lower their risk of developing melanoma, among other relevant topics regarding melanoma.  To watch the complete playlist, click here. 

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Glad to help.  FYI, I just edited the link, which has the agenda and links to oncologists' bios. Plus, the link is also on our home page, https://cancergrace.org/

Hope to see...

Recent Comments

JOIN THE CONVERSATION
Glad to help.  FYI, I just…
By JanineT GRACE … on
I was searching for this,…
By LilahStapleton on
Hi and welcome.  I'm sorry…
By JanineT GRACE … on
Hi amitchouhan,

Welcome to…
By JanineT GRACE … on